Amy received her Ph.D. in Neuroscience from the University of Northwestern in 2002 and has over 20 years of experience developing therapies for neurodegenerative disease. She has significant experience working with genetic models of disease, developing novel gene-based therapeutics, and generating pk/pd data to support drug discovery programs. She got her start at Bristol Myers Squibb where she had a leadership role in both Schizophrenia and Alzheimer’s disease programs. She also led a large in vivo screen to support a collaboration with Lexicon Genetics, designed to identify new therapeutic targets by knocking out the druggable genome. In 2016, Amy relocated to San Francisco to assume the role of Head of Translational Neuroscience at Genentech. Her team supported preclinical studies across neurodegenerative disease areas including Amyotrophic Lateral Sclerosis. In 2022, Amy chose to move to Target ALS to fully dedicate her time and efforts to ALS. Here, along with an amazing team of scientists, she leads the growth of the science portfolio including AGRI, a large ALS Global Research Initiative to collect 6000 Long Read Genomes.